Clinically relevant mutated genes that were chosen were as follows: FGFR3 in BLCA with an AUROC of 0.78 (0.72–0.822, p < 0.001), IDH1 in LGG with 0.764 (0.735–0.805, p < 0.001) and BRAF in HNSC with 0.79 (0.739–0.977, p = 0.001). The gene discussed is BRAF; the disease is bladder transitional cell carcinoma.